Document:

Amendment to Development and License Agreement

 Exhibit 10.9 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406. 
 THIS
AMENDMENT AGREEMENT (“Amendment Agreement”) is entered on the day of 3 August, 2007. 
 BETWEEN 

 

	(1)	JAGOTEC AG, a Swiss company having its place of business at Eptingerstrasse 51, CH-4132 Muttenz, Switzerland; and 

 

	(2)	SKYEPHARMA AG, a Swiss company having its place of business at Eptingerstrasse 51, CH-4132 Muttenz, Switzerland; and 

 

	(3)	NITEC PHARMA AG, a Swiss corporation having a place of business at Kagenstrasse 17, CH-4132 Reinach, Switzerland (together the “Parties”)

 Whereas: 
  

	(A)	The Parties entered into a development and licence agreement dated 20 August 2004 (the “DLA”) and wish to amend the same in accordance with the terms of
this Amendment Agreement. 

 NOW THEREFORE, in consideration of the mutual premises herein given, the parties agree to amend
the DLA as follows: 
  

	1.	Definitions 

 Unless
otherwise defined in this Amendment Agreement, all capitalised terms shall have the meanings attributed to them in the DLA. 
  

	2.	Amendments to the DLA 

The parties agree to the following amendments: 
  

	2.1	the definition “Active Drug” shall be deleted and replaced with “shall mean any “glucocorticoid” including cortisone,
hydrocortisone, prednisone, prednisolone, methylprednisolone, budesonide, dexamethasone, fludrocortisone, fluocortolone, cloprednole, deflazacort, triamcinolone, and the corresponding salts and esters thereof of a quality suitable for the
manufacture of Product meeting the Specifications”; 

  

	2.2	the definition “Product” shall be amended by adding the words “any glucocorticoids” and by deleting “prednisone, prednisolone and/or
methylprednisolone” after the word “containing”. 

	3.	Effective Date 

 This
Amendment Agreement shall become effective upon signature by both parties and shall remain in full force and effect until termination or expiry of the DLA. 
  

	4.	Remaining Terms of the DLA 

  

	4.1	The Parties acknowledge and agree that as (a) at the date hereof Nitec and Jagotec have pursuant to the DLA developed a Product containing Active Drug Prednisone
(“Existing Product”) and (b) on or around the date hereof Nitec and Jagotec have entered into a Jagotec Manufacturing Agreement in respect of such Existing Product. 

 

	4.2	The DLA contained provision for the development of the Existing Product in accordance with a Development Plan attached thereto which contained time lines which have now
passed. Should Nitec develop a Product other than the Existing Product (“New Product”), it shall notify Jagotec and with such notification provide Jagotec with information reasonably sufficient for Jagotec to decide whether or not it
wishes to participate in joint development of such New Product (together the “Notification”). Upon receipt of such information the parties shall discuss the terms of a development plan for the New Product and such changes to the DLA as may
be necessary and agreed between Jagotec and Nitec to reflect the existence of more than one Product and as are required by Jagotec in connection with carrying out development and other services, including but not limited to an amendment to the
hourly rate specified therein and agreement to new timelines. Jagotec may decide in its discretion to participate or not to participate in joint development of the New Product. If (a) Jagotec informs Nitec that it has decided not to participate
in joint development or (b) the Parties have not agreed terms for such joint development within [...***...] of receipt of Nitec’s Notification, clause 2 of the DLA shall not apply to the New Product and Nitec shall be allowed to
develop such New Product with a third party on terms no better than those last proposed by Nitec. 

  

	4.3	After the conclusion of any further joint development of the New Product, any manufacture by Jagotec of such New Product shall be subject to Nitec and Jagotec agreeing
terms of a further Jagotec Manufacturing Agreement in relation thereto. 

  

	4.4	All the provisions of the DLA not specifically modified by this Amendment Agreement shall remain in full force and effect. 

***Confidential Treatment Requested 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment Agreement to be executed by its
duly authorised officer or representative. 
  

													
	Signed by:	 		 	Signed by:	 		 	
			
	for and on behalf of JAGOTEC AG	 		 	for and on behalf of NITEC PHARMA AG
						
	Name: 	 	 /s/ F Patalano S Halseiser
	 		 	Name: Jochen Mattis	 		 	Achim Schäffler
		 	F Patalano S Halseiser	 		 	 /s/ Jochen Mattis
	 		 	 /s/ Achim Schäffler

						
	Position:	 		 		 	Position: 	 		 	 Position:

	Director 	 		 	Managing Director	 		 	EVP R&D/Prod
	Date:	 	3 August 2007	 		 	Date:	  	03 August 2007

  

			
	Signed by:
	
	for and on behalf of SKYEPHARMA AG
		
	Name: 	 	 /s/ F Patalano S Halseiser

	       F Patalano S Halseiser

		
	Position:	 	Director Director
	Date: 	 	3 August 2007Manufacturing and Supply Agreement

 Exhibit 10.10 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406. 

MANUFACTURING & SUPPLY AGREEMENT 

This MANUFACTURING & SUPPLY AGREEMENT (“Agreement”), effective as of 3 August 2007, is entered into between NITEC
PHARMA AG, a Swiss corporation having a place of business at Kägenstrasse 17, CH-4153 Reinach, Switzerland (hereinafter referred to as “NITEC”), and JAGOTEC AG, a Swiss corporation having a place of business at
Eptingerstrasse 51, CH-4132 Muttenz, Switzerland (hereinafter referred to as “JAGOTEC”; (NITEC and JAGOTEC hereinafter sometimes referred to as “Party” or “Parties”). JAGOTEC is a 100% owned
subsidiary of SkyePharma plc and SkyePharma AG is a 100% owned subsidiary of SkyePharma plc. 
 WHEREAS, the Parties and SkyePharma
AG signed a Development and Licence Agreement on 20 August 2004 (“DLA”); and 
 WHEREAS, NITEC is a company
engaged directly or through its affiliate Nitec Pharma GmbH in the manufacture, distribution and licensing of pharmaceutical products, including the Product (as defined below), and is interested in JAGOTEC manufacturing Product for use, marketing,
distribution and sale by itself, Nitec Pharma GmbH or a third party in the Territory (as defined below) under the terms and conditions of this Agreement; and 

WHEREAS, JAGOTEC is a company engaged and specialised directly or through its affiliate SkyePharma SAS - inter alia - in the
manufacturing of pharmaceutical products and is interested to manufacture Product for NITEC for use, marketing, distribution and sale by itself or a third party in the Territory under the terms and conditions of this Agreement. 

NOW, THEREFORE, for and in consideration of the premises, mutual covenants and agreements contained herein, and intending to be legally bound
hereby, the Parties hereby agree as follows: 
  

	1.	Definitions 

 For purposes
of this Agreement, the terms defined in this Artide 1 shall have the following meanings: 
  

	1.1	“Active Ingredient” shall mean prednisone in a form meeting the Specifications and the Quality Agreement and ordered by NITEC from a third party
in accordance with Section 5. 

  

	1.2	“Affiliate” shall have the meaning given to it in the DLA. 

 

	1.3	 “Auxiliary Materials” shall mean any and all material, ingredients and components required and/or necessary for the manufacturing of
Product under 

  

 1. 

	 	 
and pursuant to the Manufacturing Process and procured by JAGOTEC from third parties in accordance with Section 5, but excluding the Active Ingredient. 

 

	1.4	“Batch” shall mean a production lot containing theoretically [...***...] units of Product of the same dosage strength (“Theoretical
Quantity”) and, at a lower actual limit, the Lower Quantity. 

  

	1.5	“Business Day” shall mean a day on which commercial banks are open for business in Lyon, France. 

 

	1.6	“Capacity Plan” shall have the meaning given to it in Section 6.1. 

 

	1.7	“Commercially Reasonable Efforts” shall have the meaning given to it in the DLA. 

 

	1.8	“Committee Members” shall have the meaning given to it in Section 6.1. 

 

	1.9	 “Contract Year” shall mean each twelve (12) months period from
1st January through
31st December during the term of this Agreement.

  

	1.10	“GMP” shall mean Current Good Manufacturing Practice in accordance with rules governing medicinal products in the European Community and the US good
manufacturing practices (CFR 210&211) and/or becoming applicable during the term of this Agreement. 

  

	1.11	“Delivery” shall mean delivery of the Product Ex Works (Incoterms 2000) by JAGOTEC to NITEC in accordance with Section 6.9.

  

	1.12	“Delivery Day” shall mean the day when the Product is Delivered to NITEC or its nominee. 

 

	1.13	“Effective Date” shall mean the date first written herein above. 

 

	1.14	“Euro” shall mean the single currency of participating members states of the EU. 

 

	1.15	“Finished Product” shall mean the Product packaged by or on behalf of NITEC for commercial release and sale. 

 

	1.16	“First Launch” shall mean the first commercial sale to a third party customer of the Finished Product in a Major Country.

  

	1.17	“Forecast” shall have the meaning given to it in Section 6.2 

 

	1.18	“Joint Product Committee” shall mean a committee established and conducted in accordance with the procedures as set forth in Section 6.1.

  

 ***Confidential Treatment Requested 

2. 

	1.19	“Launch Period” shall mean the period of manufacturing Product for First Launch and for the next Contract Year after said First Launch.

  

	1.20	“Lower Quantity” shall mean [...***...] per Batch or if more than one batch is ordered at one time, the average of all such Batches
ordered of the same strength. 

  

	1.21	“Major Capital Expenditure” shall mean the investment by JAGOTEC at the Manufacturing Site including in equipment, zoning and any utilities, totalling
in excess of [...***...] for the expansion of overall capacity for the manufacture of Product (as opposed to mere replacement). 

  

	1.22	“Major Country” shall mean France, Germany, Italy, Spain, the United Kingdom or the United States of America. 

 

	1.23	“Manufacturing Costs” shall mean with respect to Product JAGOTEC’s fully allocated manufacturing costs applied by JAGOTEC to the Product
calculated in accordance with generally accepted accounting principles in Switzerland, and shall include but not be limited to [...***...]. Manufacturing Costs shall not include costs for Auxiliary Materials and Active Ingredient.

  

	1.23	“Manufacturing Process” shall mean the process for the manufacturing of Product as submitted in the request for registration of Product to any
Regulatory Authority in the Territory attached hereto as part of the Quality Agreement. 

  

	1.24	“Manufacturing Site” shall mean the facilities designated by JAGOTEC for manufacturing Product under this Agreement, which facilities are operated by
JAGOTEC’s Affiliate SkyePharma Production S.A.S. and which are located at [...***...]. 

  

	1.25	“Marketing Authorization” shall mean with respect to any country that the applicable health authority has approved Finished Product for marketing in
such country. 

  

	1.26	“Minimum Commercial Yield” shall mean the minimum yield in % of a Batch manufactured according to the Manufacturing Process for market purposes as set
forth in Section 8. 

  

	1.27	“Non-Compliant/Non-Compliance” shall have the meaning given to it in 6.14. 

 

	1.28	“Quality Agreement” shall mean the agreement dated as of the Effective Date on cGMP which agreement shall be attached hereto as Annex 5.

  

 ***Confidential Treatment Requested 

3. 

	1.29	“Price Per Unit” shall mean the price per unit of Product manufactured and supplied hereunder composed of the [...***...] of the
Manufacturing Costs plus [...***...] of the costs of the Auxiliary Materials. Costs of the Active Ingredient are not included. The Price per Unit shall be as set out in Annex 4 for the period referred to therein. 

 

	1.30	“Product” shall mean the pharmaceutical formulation named Lodotra containing the Active Ingredient manufactured and supplied hereunder by JAGOTEC in
accordance with the Quality Agreement including the Manufacturing Process and the Specifications, which have been approved for marketing and sale by Regulatory Authorities in the Territory or which are intended to use for commercialisation purposes
or clinical trials. Product is offered in the presentation according to Annex 1. 

  

	1.31	“Regulatory Approvals” shall mean all approvals, price approvals or approvals for reimbursements, product and/or establishment licenses, registrations,
permits, or authorizations (including Marketing Authorizations) of any federal, state or local regulatory agency, department, bureau or other governmental entity or Regulatory Authority, necessary for the manufacture, packaging, distribution, use,
storage, importation, export, transport, marketing and sale of the Products and/or Finished Products for therapeutic use in humans in a country of the Territory. 

 

	1.32	“Regulatory Authority/(ies)” shall mean any governmental authority in any country or group of countries of the Territory competent to approve
pharmaceutical products for manufacturing, marketing, distribution and sale in any country(ies) of the Territory and/or to approve the price for pharmaceutical products to be sold in any country(ies) of the Territory, including without limitation
the FDA and EMEA, and any successor agency thereof. 

  

	1.33	“Regulatory Standards” shall mean all standards, rules and regulations promulgated by a Regulatory Authority and applicable to the product and the
manufacture thereof, including without limitation cGMP. 

  

	1.34	“Release” shall mean release of the Product by the Qualified Person pursuant to the Quality Agreement. 

 

	1.35	“Shelf Life” shall mean in relation to the Product have the meaning given to it in the Quality Agreement/shall mean in respect of each Batch a defined
period of months (“Shelf Life Period”) as per Annex 2a which will be updated from time to time by NITEC) from the date of first contact between the Active Ingredient and Auxiliary Material. 

 

	1.36	“Specifications” shall mean the specifications for the Product as contained in Annex 2. 

 

 ***Confidential Treatment Requested 

4. 

	1.37	“Technical Support” shall mean reasonable assistance provided by JAGOTEC to NITEC strictly limited to providing technical support to an alternative
supplier of Product in connection with (a) the training of their staff, (b) cross-validation of the analytical methods and its production of three consecutive validation Batches (of one strength only) complying with the Specifications. All
other technical support, including but not limited to regulatory support, stability programs and any in vivo study work, is specifically excluded. 

  

	1.38	“Territory” shall mean collectively each country or group of countries of the world, in which a Regulatory Authority has granted Regulatory Approval.

  

	2.	Subject Matter and Grant of License 

NITEC hereby instructs JAGOTEC, and JAGOTEC hereby agrees under the terms and conditions contained in this Agreement, to manufacture at
the Manufacturing Site and supply to NITEC Product in bulk form for use in the Finished Product for sale to the pharmaceutical trade. JAGOTEC shall manufacture and deliver Product exclusively to NITEC. JAGOTEC shall delegate its responsibilities
hereunder to its Affiliate SkyePharma SAS, provided that JAGOTEC remains solely liable to NITEC for the same. The use, marketing, distribution and sale of the Finished Product may at NITEC’s option also be carried out by NITEC’s affiliate
Nitec Pharma GmbH and NITEC may delegate any other responsibilities under this Agreement to Nitec Pharma GmbH so long as NITEC remains solely liable to JAGOTEC for the same. 

 

	3.	Manufacturing of Product 

  

	3.1	 JAGOTEC shall manufacture the Product for marketing and sale by NITEC in the Manufacturing Site in strict compliance with the Specifications and the
approved Manufacturing Process and in accordance with the Quality Agreement. Furthermore, JAGOTEC shall only use such equipment and personnel which are appropriate or duly qualified for the manufacturing of Product in accordance with the provisions
of this Agreement and the Quality Agreement. It is acknowledged and agreed between the parties that the final dissolution specification for the Product is not approved by the regulatory authorities at signing this contract but will be approved by
the regulatory authorities during the approval process. Therefore, JAGOTEC shall only be liable for failing to manufacture the Product in accordance with such preliminary dissolution specification (as per annex 2) until agreement of the Joint
Product Committee as set out below. After approval by the regulatory authorities of a final dissolution specification, JAGOTEC shall use Commercially Reasonable Best Efforts to implement such final dissolution specification such that the Product may
be manufactured at the Manufacturing Site in accordance therewith. If, having used such efforts, JAGOTEC is able to manufacture in accordance with such final dissolution specification, it shall notify the Joint Product Committee. Upon the unanimous
agreement of the Joint Product Committee that such final dissolution specification has been implemented, the Specifications and/or the 

 

 5. 

	 	 
Quality Agreement shall be amended to incorporate such final dissolution specification and JAGOTEC agrees that the campaigns following such amendment shall be manufactured in accordance
therewith. If, having used Commercially Reasonable Best Efforts to do so, Jagotec is unable to manufacture Product in accordance with such final dissolution specification within a reasonable period of time following approval, it shall continue to
manufacture in accordance with the Specifications at the date hereof, shall not be in breach of this Agreement and shall have no liability to NITEC in connection with such failure. In this clause, “Commercially Reasonable Best Efforts”
shall mean those efforts and resources that would be used by an established pharmaceutical company in its capacity as a contract manufacturer (taking into all relevant factors including but not limited to product labelling, stage in the relevant
product life, market potential, past performance, availability of resource, economic return, the regulatory environment and competitive market conditions in the therapeutic area), utilizing sound and reasonable scientific and business practice and
judgment and its manufacturing expertise, in a diligent and timely manner, all as measured by the facts and circumstances at the time such efforts are due; it being understood however for the avoidance of any doubt that such efforts shall not
include, nor shall be deemed to include, (a) the commitment by JAGOTEC to any Major Capital Expenditure and (b) any obligation on JAGOTEC to manufacture and supply the Product at less than a reasonable margin. 

 

	3.2	 JAGOTEC shall permit duly authorized representatives of (a) NITEC or (b) any third party contracted by NITEC to have an official
responsibility for the release of the Finished Product to the market according to applicable laws and regulations applying in countries of the Territory (so long as such third party has signed a confidentiality agreement on terms acceptable to
JAGOTEC) during Business Days and hours and upon reasonable prior written notice to inspect once a year (or more often if reasonably requested by NITEC on its own behalf or on behalf of its third party contractor) the Manufacturing Site - including
but not limited to manufacturing, testing, warehousing and/or storing and generation and/or disposal of waste - used for the manufacturing of Product and to inspect and take reasonable quantities of Active Ingredient, Auxiliary Materials,
intermediate product and Product manufactured for examination purposes to verify JAGOTEC’s compliance with the Manufacturing Process, the Specifications and its obligations under this Agreement including the Quality Agreement. Furthermore,
JAGOTEC will supply copies to NITEC (on NITEC’s request and at NITEC’s cost) of any and all records relating to manufacturing and testing of the Product. NITEC shall be promptly informed in writing and by fax or email if and when an
inspection by a Regulatory Authority occurs or is scheduled to occur at the Manufacturing Site which in any way involves inspection of the production of Product or any other feature of JAGOTEC’s actions in connection with Product of the
performance of this Agreement. NITEC shall be entitled to send a representative to attend any such 

 

 6. 

	 	 
inspection of the Manufacturing Site. The findings of any such inspection at the Manufacturing Site or of any other inspections including self inspections carried out in relation to production at
the Manufacturing Site of JAGOTEC for the Product shall promptly be made known in their entirety in writing to NITEC insofar and to the extent that they may potentially impact the commercialization, manufacture (including but not limited to quality
and testing) and Delivery of the Product under this Agreement. 

  

	3.3	JAGOTEC undertakes to use any and all Active Ingredient exclusively for the performance of its obligations hereunder and JAGOTEC shall, upon receipt of any supply of
Active Ingredient and Auxiliary Materials, promptly perform the quality and quantity control procedures as provided for in the Quality Agreement. In the event that any Active Ingredient and Auxiliary Materials to be used solely in the manufacture of
the Product, or any part thereof, do not meet with the Specifications and/or quality requirements as set forth in the Quality Agreement, then JAGOTEC shall reject such materials and shall promptly notify NITEC thereof in writing - including a
specific description of the deviation from the Specifications—(a) in every case in relation to Active Ingredient and (b) where such rejection is reasonably likely to impact upon the manufacture of the Product in relation to Auxiliary
Materials. The cost of any rejected Auxiliary Materials, the quality control and related rejection for Auxiliary Materials shall be borne by Jagotec or its suppliers subject to the terms of existing supply agreements between Jagotec and its
suppliers of Auxiliary Materials. The cost of any rejected Active Ingredient, quality control and rejection for Active Ingredient shall be borne by NITEC or its selected supplier subject to the terms of any existing supply agreement between NITEC
and the Active Ingredient supplier unless this failure is caused by a failure of JAGOTEC during the quality control process for the Active Ingredient. 

  

	3.4	JAGOTEC shall store all Active Ingredient, Auxiliary Materials, intermediate product and all Product manufactured hereunder, in a suitable warehouse under suitable
conditions as set forth in the Quality Agreement preventing the deterioration, theft or damage of Active Ingredient, Auxiliary Materials, intermediate products and Product until the agreed Delivery Day to NITEC, and JAGOTEC shall insure against such
risks all Active Ingredient, Auxiliary Materials, intermediate products and all Product manufactured hereunder until Delivery. 

The Active Ingredient ordered by NITEC for the purposes of manufacturing of Product shall remain NITEC property but shall be stored by
JAGOTEC under JAGOTEC’s sole responsibility. 
 JAGOTEC shall report to NITEC at least once a month on the level of stocks
of Active Ingredient, and Product manufactured, including a differentiation of the status of the Product manufactured, such as “under quarantine”, “released”, “rejected”). The report frequency may be modified by
decision of the Joint Product Committee. 
  

 7. 

 Should Auxiliary Materials ordered exclusively for NITEC need to be re-analysed after being
stored by JAGOTEC in compliance with the Quality Agreement for a period in excess of its intended shelf-life, NITEC shall cover the cost of such analysis. Should Active Ingredient or Auxiliary Materials require re-analysis due to failure to comply
with the storage provisions of the Quality Agreement, or where such re-analysis is carried out by JAGOTEC for its own internal purposes, then JAGOTEC shall cover the cost of such analysis. 

 

	3.5	JAGOTEC hereby agrees to guarantee NITEC, upon two week’s prior written notice, free and full access to any know-how relating to the manufacture of the Product
necessary to enable NITEC to obtain or maintain any Regulatory Approval in the Territory, to perform the Batch release, to ensure that the finished Product is in line with the Regulatory Approval and all other (local) applicable laws and regulations
and to enable qualified NITEC personnel to fulfil NITEC’s legal and regulatory obligations. 

 Each change in
the Product or in the Manufacturing Process proposed by either Party, shall be communicated to the other Party in advance, to enable the other Party to comment on such intended changes before implementation. Any changes proposed by JAGOTEC shall
only be implemented with NITEC’s prior written consent, which consent shall not be unreasonably withheld or delayed. The Joint Product Committee shall discuss any benefit generated by the implementation of changes proposed by JAGOTEC and decide
which party shall bear which proportion of the costs thereof. NITEC shall bear or reimburse JAGOTEC for all of JAGOTEC’s costs (including without limitation any regulatory costs) associated with any change initiated by NITEC or required by a
Regulatory Authority and related specifically to the Product. Further details regarding the change control procedure will be set forth in the separate Quality Agreement. 

 

	3.6	Quality control of Product is under the sole responsibility of NITEC. Therefore JAGOTEC will not analyze the Product in order to determine its suitability for quality
control under this Agreement or applicable requirements of a Regulatory Authority or with any applicable Regulatory Approval. All in-process controls are under the sole responsibility of JAGOTEC. JAGOTEC will not change the in- process controls as
set forth in the Regulatory Approval and the Quality Agreement without the written consent of NITEC. 

 JAGOTEC
shall provide NITEC with the results of the in-process controls after occurrence and with samples of Product to perform the quality control testing within 3 working days of the final press-coating step. NITEC shall inform JAGOTEC on the results of
such analysis also within 3 working days of completion. 
 In the event that JAGOTEC agrees to the implementation of the
analytical method (quality control)for Product at JAGOTEC, NITEC shall reimburse 
  

 8. 

 
JAGOTEC for all of JAGOTEC’s reasonable costs associated with such analytical method transfer, to the extent JAGOTEC has notified NITEC in advance of the estimated amount of such costs.
Otherwise, each Party shall bear its own costs related to such analytical method transfer. 
  

	3.7	Without prejudice to Section 3.6, JAGOTEC shall perform all in-process control tests and confirm the GMP-compliant manufacture of the Product pursuant to the terms
of the Quality Agreement. 

  

	3.8	JAGOTEC agrees to provide sufficient manufacturing capacity subject to the terms hereof to fulfil NITEC’s requirements for the Product as bulk tablets, to the
extent that these requirements of NITEC are reflected in NITEC’s Forecast per Section 6.2 and in JAGOTEC’s Capacity Plan per Section 6.1. 

 

	4.	Obligations of NITEC 

  

	4.1	NITEC shall be responsible, at its own cost and expense, for maintaining and updating from time to time, if needed, any and all Regulatory Approvals.

  

	4.2	NITEC shall appoint a supplier of Active Ingredient and shall ensure that such supplier supplies Active Ingredient in a timely manner which meets with the
Specifications and/or quality requirements as set forth in the Quality Agreement. NITEC agrees that for the avoidance of any shortfalls during the Launch Period it will order [...***...] of the Active Ingredient required for the
manufacturing of Product (as recommended by JAGOTEC pursuant to clause 5.1, firmly ordered by NITEC). 

  

	4.3	NITEC shall be responsible for the qualification of the supplier of the Active Ingredient as set forth in the Quality Agreement. 

 

	4.4	NITEC shall contract with such supplier, be responsible for all dealings with, and settle all invoices of such supplier. NITEC shall negotiate with each such qualified
supplier prices, annual amounts and lead times for the supply of the Active Ingredient. NITEC shall inform JAGOTEC in writing of the relevant parts of the agreements between NITEC and the suppliers of the Active Ingredient. 

 

	4.5	NITEC shall ensure that such supply of Active Ingredient shall be in compliance with the Specifications and the requirements set forth in the Quality Agreement, and
shall be delivered DDP (Incoterms 2000 ICC) to the Manufacturing Site. 

  

	4.6	NITEC shall notify JAGOTEC of any matter of which it becomes aware which is reasonably likely to impact upon the delivery or quality of the Active Ingredient to
JAGOTEC. 

  

 ***Confidential Treatment Requested 

9. 

	5.	Obligations and Responsibilities of JAGOTEC 

  

	5.1	JAGOTEC undertakes to recommend a supplier of the Auxiliary Materials which JAGOTEC shall contract with and from which JAGOTEC shall order the same for the purposes
hereof. 

  

	5.2	JAGOTEC shall be responsible for the qualification of the supplier of the Auxiliary Materials as set forth in the Quality Agreement. 

 

	5.3	JAGOTEC shall negotiate with each such qualified supplier prices, annual amounts and lead times for the supply of the Auxiliary Materials. JAGOTEC shall inform NITEC in
writing of the agreements between JAGOTEC and the suppliers of the Auxiliary Materials. 

  

	5.4	JAGOTEC shall be responsible for the keeping of the contract with the supplier and the usage of Auxiliary Materials for manufacturing of Product which meet with the
Specifications and/or quality requirements as set forth in the Quality Agreement. 

 For the avoidance of any
shortfalls during the Launch Period JAGOTEC shall order [...***...] of the Auxiliary Materials required for the manufacturing of Product firmly ordered by NITEC. JAGOTEC shall ensure that such supply of Auxiliary Materials shall be in
compliance with the requirements set forth in the Quality Agreement, and shall be delivered DDP (Incoterms 2000 ICC) to the Manufacturing Site. 
  

	5.5	Any change in the supplier or the specification of the Auxiliary Materials shall require the prior written consent of NITEC. 

 

	5.6	JAGOTEC shall notify NITEC of any matter of which it becomes aware which is reasonably likely to impact upon the Delivery Day or otherwise on JAGOTEC’s ability to
fully and timely perform its obligations under this Agreement. 

  

	5.7	JAGOTEC may provide support in relation to technology transfer other than Technical Support to NITEC upon agreement by NITEC to the payment of such costs of providing
such support as are agreed. 

  

	6.	Order and Supply of Product 

  

	6.1	 The parties shall establish a “Joint Product Committee” consisting of four (4) individuals (“Committee Members”); two
of whom shall be nominated by JAGOTEC and two of whom shall be nominated by NITEC. The Committee Members may be replaced by notice to the other Party and shall be appropriately qualified and experienced in order to make a meaningful contribution to
the Joint Product Committee meetings. The Joint Product 

  

 ***Confidential Treatment Requested 

10. 

	 	 
Committee shall meet at least once per quarter to review NITEC’s Forecast (as defined in Section 6.2) for the Product, which shall reflect NITEC’s realistically anticipated up-side
scenario for its requirements for Product. JAGOTEC shall provide to NITEC, at the beginning of each quarter for the following eight quarters with a capacity plan for the Product (“Capacity Plan”). The Joint Production Committee
shall compare the Capacity Plan to NITEC’s Forecast. Each member of the Committee shall have one vote in relation to matters discussed by it and save as otherwise set out herein votes shall be carried by a majority. Initial members of the
Committee shall be set out in Annex 9. 

  

	6.2	NITEC shall issue, for the first time on the date of signature hereof, and thereafter during the term of this Agreement at the beginning of each quarter in accordance
with Section 6.3, a rolling forecast (“Forecast”) for the upcoming [...***...] estimating NITEC’s requirements of Product for (a) distribution and sale and (b) for clinical studies in the Territory,
which forecasts shall be used by JAGOTEC for production planning purposes. The submission of each Forecast shall constitute a binding order for the quantity of Product set forth in [...***...] for Delivery at the latest [...***...] after
the submission thereof save that the quantities set forth in [...***...] of the first Forecast issued on the date of signature of this Agreement shall not be binding on the parties unless agreed between them. In each Forecast,
[...***...] shall be (i) within +/- [...***...] of the quantities of the Product set out in [...***...] in the Forecast immediately preceding the most recent Forecast and (ii) within +/- [...***...] of the
quantities set out in [...***...] in the forecast immediately preceding the Forecast referred to in (i). Save as set out herein, it is mutually agreed between the Parties that the Forecast is only a non-binding estimate of NITEC’s
requirements of the Product and that in particular in case of any foreseeable launches in a Major Country such Forecast may be adequately adjusted by mutual agreement of the parties. 

 

	6.3	 Any purchase order (to be sent out by NITEC on a monthly basis) shall be confirmed by JAGOTEC within 5 working days and shall be binding upon JAGOTEC,
provided that the requested Delivery Day is not earlier than [...***...] after the receipt of such purchase order and provided that such order shall correspond with the binding element of the Forecast for the month in question. It is
JAGOTEC’s obligation to negotiate with the Auxiliary Materials supplier lead times for the supply of the Auxiliary Materials in quantities and of quality sufficient for timely manufacturing of Product in accordance with any [...***...]
Forecast. JAGOTEC shall recommend to NITEC and its Active Ingredient supplier (a) the quantity of Active Ingredient and (b) the dates of delivery of the same which would, in JAGOTEC’s reasonable opinion based on Forecasts, be required
in order for JAGOTEC to timely manufacture Product in accordance with any [...***...] Forecast. Further JAGOTEC shall inform NITEC at the same time about the existing stock of Active Ingredient held by JAGOTEC. JAGOTEC shall not be responsible
for any other dealings with such 

  

 ***Confidential Treatment Requested 

11. 

	 	 
supplier nor shall it be liable for the failure of such supplier to supply Active Ingredient in a timely manner or that does not meet with the Specifications and/or quality requirements as set
forth in the Quality Agreement. JAGOTEC shall inform NITEC immediately in writing of any deviation from the aforementioned [...***...] lead time. 

 

	6.4	Notwithstanding anything contained herein, NITEC may always request supply of Product in excess of the quantity set out in Section 6.3 but any such request shall
not be considered a firm order binding upon JAGOTEC unless and to the extent confirmed by JAGOTEC in writing, provided that JAGOTEC shall at all times employ its Commercially Reasonable Efforts to comply with any request of NITEC for Product.

  

	6.5	If (a) in any three consecutive Forecasts, the quantity forecast in respect of [...***...] thereof would, in JAGOTEC’s sole opinion, require
Major Capital Expenditure in order for JAGOTEC to manufacture such quantity (JAGOTEC basing such opinion upon it deciding in its sole discretion that the quantity forecast exceeds the quantity that it could provide on the date of each such Forecast
by [...***...] of the maximum available capacity for NITEC as per Capacity Plan would be required), and (b) in the third such consecutive Forecast, the quantity forecast in respect of [...***...] thereof would so require Major
Capital Expenditure, JAGOTEC within [...***...] of receipt of the third such consecutive Forecast shall notify NITEC and decide, whether or not to commence such Major Capital Expenditure. If JAGOTEC commences such Major Capital Expenditure
NITEC agrees and acknowledges that such Major Capital Expenditure is likely to take [...***...] to complete 

  

	6.6	If JAGOTEC decides, upon receiving the third such consecutive Forecast as set out in Section 6.5 above, not to commence Major Capital Expenditure it shall notify
NITEC of its decision and any subsequent [...***...] Forecast shall only become binding as to the quantity that JAGOTEC is able to manufacture without such Major Capital Expenditure. Upon such decision not to commence Major Capital
Expenditure, NITEC shall be entitled to qualify one second manufacturing site on the foregoing conditions. NITEC may, from the date upon which the third consecutive [...***...] forecast becomes a [...***...] Forecast, as set out in
Section 6.5, use such second manufacturing site to fulfil in any subsequent quarter only such amount of orders as exceed those which JAGOTEC is unable to manufacture as a result of not commencing Major Capital Expenditure. JAGOTEC shall in such
circumstance provide Technical Support to NITEC at NITEC’s cost. 

  

	6.7	 Each order under Section 6.2 above shall consist of not less than [...***...] Batches of Product covering all dosage strengths (save that in
the first two years following First Launch Jagotec agrees to accept individual orders of less than [...***...], without prejudice to the minimum order obligation in the following sentence. NITEC shall order the minimum quantities set out and
according to Annex 3 (the “Minimum Quantities”). The firm order for launch 

  

 ***Confidential Treatment Requested 

12. 

	 	 
stock is at least 1 Batch of Product per dosage strength. NITEC will place orders of Product in units of whole Batches. 

 

	6.8	It is agreed and understood between the parties that the quantities ordered by NITEC shall be based upon the fact that each Batch (or the average of a number of Batches
where more than one Batch is ordered at any one time) may contain [...***...] of units and such Lower Quantity would be, if Delivered, sufficient to satisfy its requirements and NITEC shall supply Forecasts accordingly.

  

	6.9	JAGOTEC shall supply Product firmly ordered by NITEC in accordance with this Agreement at the applicable and agreed Delivery Day upon the preceding and following
conditions; (a) Any Batch (or number of Batches on average as set out in Section 6.8) of Product may not fall short of the Lower Quantity; and (b) All Products shall be Delivered to NITEC Ex Works (Incoterms 2000) the Manufacturing
Site. Together with any such shipment of Product, JAGOTEC shall provide NITEC with the documents and samples specified in the Quality Agreement. JAGOTEC shall be responsible for ensuring that each Delivery of Product shall be delivered to NITEC as
soon as possible (and in any event within 3 months) after its manufacture. 

  

	6.10	Delivery performance and failures. Orders are considered as orders fulfilled on time if the Products meet the standards set out in the Quality Agreement and not
properly rejected on the terms hereof and if the Delivery Day set out in an order acceptance is met by [...***...]. In the case that JAGOTEC does not reach the on time targets above, JAGOTEC shall use all Commercially Reasonable Efforts to
fulfil such orders and NITEC shall, in addition to any other remedy (including under Section 8 in any case in which the Minimum Commercial Yield is not achieved), be entitled to reduce the Price Per Unit of late batches by [...***...] of
delay but to a maximum of [...***...] 

 If JAGOTEC produces a Batch or Batches (on average as above)
containing less than the Lower Quantity JAGOTEC shall immediately inform NITEC in writing. NITEC will thereafter be entitled to place an additional order (not defined as or part of any Minimum Orders) and JAGOTEC agrees to use Commercially
Reasonable Efforts to accept and fulfil this order within such a shortened lead time as is reasonably practicable (and to within five days provide NITEC with a Delivery Day therefor) provided that such quantities of Active Ingredient and Auxiliary
Materials are on stock in order to do so. To avoid any shortfalls during the Launch Period the Parties hereby agree (in Sections 4.2 and 5.4) to order [...***...] of Active Ingredient and Auxiliary Materials respectively of the amount firmly
ordered by NITEC during such Launch Period. 
  

 ***Confidential Treatment Requested 

13. 

 NITEC shall then be obliged to pay the following amounts in respect of the additionally
ordered Batches as set out above; 
  

	 	(a)	in respect of units up to the total Minimum Commercial Yield ordered – the Price Per Unit; 

 

	 	(b)	in respect of the balance of supplied units (i.e. in excess of the Minimum Commercial Yield ordered) – the Price Per Unit [...***...]

 JAGOTEC shall not keep Product on stock except for the purpose of retaining samples as defined in the quality
agreement or as required for analysis in case of a dispute pursuant to clause 6.17 or otherwise. 
  

	6.11	JAGOTEC shall notify NITEC of the Delivery Date for a Delivery at least five (5) days prior of the same and NITEC undertakes to accept Delivery of all Product
Delivered by JAGOTEC on such Delivery Date. JAGOTEC will package and label Product in accordance with the provisions of the Quality Agreement including at least code number, name of product, batch number, order number, quantity of supplied Product
per package and date of manufacture. 

  

	6.12	If following completion of Major Capital Expenditure NITEC does not order quantities equal to (a) those in the Forecasts which triggered such Major Capital
Expenditure [...***...] and (b) that forecast in respect of [...***...] in the subsequent Forecast, the Price Per Unit of quantities actually ordered will be adjusted as follows; 

Where the amounts ordered by NITEC are less than [...***...] but more than [...***...], of maximum available capacity: Price
Per Unit [...***...] 
 Where the amounts ordered by NITEC are [...***...] or less, but more than [...***...]
of maximum available capacity: Price Per Unit [...***...] [...***...] 
 Where the amounts ordered by NITEC are
[...***...] or less of maximum available capacity: Price Per Unit [...***...] 
 The maximum available capacity for
the purposes of this Section 6.12 shall be that available for NITEC as per Capacity Plan at the date upon which JAGOTEC notified NITEC of the need for Major Capital Expenditure under Section 6.5. 

Any amounts in respect of an increase in prices due under this Section 6.12 shall be invoiced at the end of the twelve month period
following completion of Major Capital Expenditure. Payment terms shall be as per order to reflect the price adjustment for the previous twelve month; payment term for this invoice will be as per Annex 4. 

 

 ***Confidential Treatment Requested 

14. 

	6.13	NITEC shall bear the cost of bulk, quality control and rejection of spoiled, damaged, contaminated or defective Active Ingredient provided that such Active
Ingredient’s damage, contamination or defect could not have been discovered by JAGOTEC with standard sampling or analytical procedures as defined in the Quality Agreement. 

 

	6.14	If any shipment of Product or any portion thereof is spoiled, damaged, contaminated or defective upon Delivery or fails to meet the Specifications or the quality
standards set out in the Quality Agreement (together “Non- Compliant”), then NITEC shall have the right to reject such shipment or the portion affected thereby by giving written notice to JAGOTEC within [...***...] following
the Delivery of such shipment of Product, sufficiently specifying the alleged Non-Compliance and the quantities affected. Any shipment or portion thereof so rejected by NITEC shall be held at JAGOTEC’s disposal for examination. JAGOTEC shall
investigate such issue and provide a written report to NITEC as soon as possible after notification. JAGOTEC shall not be liable for any Non-Compliance of the Product arising out of the shipment, storage or handling of Product by NITEC or its
representatives, agents or customers. 

  

	6.15	In the event that any shipment of Product or any portion thereof is rightly rejected by NITEC in accordance with Section 6.14 above, then JAGOTEC undertakes to
take back and, at NITEC’s request, destroy such Non-Compliant Product, and to replace such Non-Compliant shipment or portion thereof with an identical quantity of Product as soon as reasonably possible. 

 

	6.16	In any case of Non-Compliance, NITEC shall pay for the Non-Compliant Product, provided that such payment shall not be deemed to be a waiver of NITEC of any of its
rights on account of such Non-Compliance. 

 Should the Non-Compliance be due to JAGOTEC, such replacement shall be
effected at JAGOTEC’s own cost and expense which includes but is not limited the corresponding amount of Active Ingredient and Auxiliary Materials in the Non-Compliant Batch or part thereof and the Manufacturing Costs. 

The Non-Compliant Product shall, at JAGOTEC’s cost and expense, be returned to JAGOTEC. 

NITEC shall pay for the replacement of Product in accordance with the payment provisions of this Agreement, provided that Product supplied
by JAGOTEC conforms with quality standards as of Annex 5. 
 Should the Non-Compliance be due to NITEC (including for the
avoidance of doubt in situations where the Active Ingredient is contaminated and such Active Ingredient contamination could not be discovered by JAGOTEC with standard sampling or analytical procedures as defined in the Quality Agreement), NITEC
shall pay for the replacement of Product in accordance with the payment provisions of this Agreement. 
  

 ***Confidential Treatment Requested 

15. 

	6.17	In the event of any dispute between the Parties regarding the question whether a shipment of Product or any part thereof timely rejected by NITEC was actually
Non-Compliant, and/or where responsibility for such Non-Compliance, under the terms hereof, lies the Parties agree to have an independent mutually acceptable (each Party acting reasonably) laboratory or expert perform such tests and analysis on the
rejected Product as deemed necessary and/or required to establish the defect alleged by NITEC and the reasons therefore. The result of such independent laboratory or expert shall be binding upon the Parties, and the cost of such examination shall be
borne by the losing Party. 

  

	6.18	In cases in which the resolution of a dispute or investigations is anticipated to take more than 2 weeks, JAGOTEC shall upon NITEC’s request and as soon as
practicable after notification of the rejection deliver replacement Products for the Products under dispute in order to ensure continuity of supply. 

  

	6.19	Together with any shipment of Product, JAGOTEC shall issue a respective invoice for such shipment, applying the then valid Price Per Unit, multiplied by the number of
units of Product actually supplied. NITEC undertakes to pay any and all such invoices within [...***...] as of the delivery date of the respective shipment of Product (“Payment Date”). In the event of late payment JAGOTEC may
charge interest on the outstanding amount at a rate of [...***...] and such interest shall be calculated and payable in respect of the period from Payment Date until the date payment in full is received by JAGOTEC. 

 

	7.	Calculation and Adjustment of Price Per Unit 

  

	7.1	The Price per Unit does not include any Value Added Taxes (VAT), turnover taxes or similar charges in any country, which are to be added and paid by NITEC as
applicable. The Price Per Unit of this Agreement shall remain applicable for all supplies of Product during the term from the Effective Date until 31 Dec 2007. 

 

	7.2	Thereafter, the Price per Unit contained in Annex 4 hereto may be adjusted by JAGOTEC once each Contract Year in the month of October calculated as follows:

  

	 	(a)	Adjustments to Manufacturing Costs shall be calculated on the basis of [...***...]; 

 

	 	(b)	Adjustments to costs of Auxiliary Materials shall be calculated by reference to actual changes to the costs thereof, without any mark up added by JAGOTEC

 In no Contract Year may any increase be in excess of [...***...] of the then current Price Per Unit save
by mutual agreement of the parties. Such adjusted Price 
  

 ***Confidential Treatment Requested 

16. 

 
per Unit shall be attached hereto as new Annex 3 each year and shall remain in force for supplies of Product during the next Contract Year. 

 

	7.3	NITEC shall have the right, through its employees and/or its independent auditing representatives and upon reasonable notice, to audit, during normal business hours,
all records and accounts of JAGOTEC as may under recognised accounting practices contain information bearing upon the Price per Unit. Such audit shall be carried out at NITEC’s expense unless it reveals that a Price Per Unit quoted by JAGOTEC
to NITEC prior to the audit exceeded the Price per Unit calculated in accordance with this Agreement by [...***...] or more, in which case JAGOTEC shall, forthwith reimburse NITEC for the cost of audit and an amount equal to the
overpayment. 

  

	8.	Minimum Commercial Yield 

JAGOTEC commits itself to attaining the Minimum Commercial Yield of the Product as set out in Annex 6 (or as may otherwise be amended on
the terms hereof). The Commercial Yield shall be calculated as follows: 
 (a +b)/c 

 

	 	a    =	number of units delivered by JAGOTEC 

  

	 	b    =	number of sample units necessary for control purposes and retaining samples 

 

	 	c    =	theoretical quantity of units per Batch of Product in bulk Tablets 

If the actual yield of Product, calculated for a maximum of one (1) year, is below the Minimum Commercial Yield, JAGOTEC shall
reimburse NITEC for a proportionate amount of the cost of Active Ingredient. 
 This Minimum Yield shall be reviewed annually to
allow for possible improvements in the Manufacturing Process. 
  

	9.	Delivery Conditions: 

JAGOTEC will deliver Product packaged and labelled in accordance with the Quality Agreement and the defined “Logistics” under
Annex 7. 
  

 ***Confidential Treatment Requested 

17. 

	10.	Term and Termination 

  

	10.1	According to the DLA this Agreement shall commence as of the Effective Date and shall continue in full force and effect until the end of the 5th year after First Launch
(“Minimum Term”). It shall be automatically extended on a yearly basis unless terminated by one Party by giving to the other at least (subject to the Section 10.2 below) twenty four (24) months’ written notice to
expire not before the end of the Minimum Term. 

  

	10.2	In the event of the payment of Major Capital Expenditure the notice period for any termination by either party to occur within [...***...] of such Major
Capital Expenditure shall be [...***...]. 

  

	10.3	Notwithstanding anything contained in Section 10.1 above, and except as otherwise explicitly provided in this Agreement, this Agreement may be terminated at any
time with immediate effect by giving written notice to that effect, as follows: 

  

	 	a)	by either Party, if the other Party is materially in default or in material breach of a term or provision hereof and such default or breach continues “and” if
curable, is not cured or remedied within [...***...] upon the other Party’s written request to cure or remedy such default or breach; or 

  

	 	b)	by either Party, if the other Party becomes insolvent or goes into liquidation, voluntarily or otherwise, other than for the sole purpose of reorganisation, or goes
into bankruptcy or makes an assignment for the benefit of creditors, or in the event of a receiver being appointed of the other Party’s property or parts thereof. 

 

	10.4	Upon the termination or expiry of this Agreement, regardless of the reason therefor, JAGOTEC shall at NITEC’s written request continue the supply of Product to
NITEC until such time as NITEC has an alternative manufacturing site approved by appropriate Regulatory Authorities for the supply of Product save that it shall be under no obligation to continue such supply for a period exceeding 24 months from the
date of such termination notice. Upon notice of termination or expiry, NITEC shall seek such an alternative manufacturing site with reasonable speed and JAGOTEC shall provide Technical Support to NITEC in relation to technical transfer issues
relating to Product to the alternative manufacturing site chosen by NITEC. If this Agreement is terminated by NITEC for JAGOTEC’s breach of this Agreement, the costs of the Technical Support shall be born by JAGOTEC. In all other circumstances
the costs of the Technical Support shall be borne by NITEC. 

  

 ***Confidential Treatment Requested 

18. 

	11.	Effects of Termination 

  

	11.1	In the event of termination or expiry of this Agreement by either Party, no compensation or indemnity shall be payable to or may be claimed by either Party from the
other Party as a result of such termination other than as set forth in this Agreement. Notwithstanding the preceding sentence, the termination of this Agreement by either Party shall not relieve the Parties of any obligation accruing prior to the
effective date of such termination. 

  

	11.2	In the event of termination of this Agreement by JAGOTEC under Section 10.2 above, NITEC shall, upon JAGOTEC’s request together with the respective
termination notice take also delivery of any and all Auxiliary Materials in stock and firmly ordered by JAGOTEC on the basis NITEC’s Forecast against payment of the net procurement price for such Auxiliary Materials paid by JAGOTEC to third
party suppliers (plus Value Added Tax, turnover tax or similar charges, as applicable). All such Auxiliary Material and Active Ingredient shall be collected by NITEC from the Manufacturing Site. 

 

	11.3	The Parties agree that in the event of termination of this Agreement for whatsoever reason, Sections 11, 12, 13 and 17 shall remain in full force and effect in
accordance with such respective provisions. 

  

	11.4	Except as otherwise explicitly provided in this Agreement, nothing contained in this Section 10 shall in any way limit, and shall be without any prejudice to, any
other rights or remedies which may be available to either Party. 

  

	12.	Indemnity and Insurance 

  

	12.1	JAGOTEC does not assume any liability or gives any representation or warranty, whether express nor implied, for the merchantability or fitness for a particular purpose
of Product or Finished Product manufactured and/or supplied hereunder except to the extent that such liability arise from the gross negligence or wilful misconduct of JAGOTEC, its Affiliates or any of its or their respective employees.

  

	12.2	In no event shall JAGOTEC be liable for any direct, indirect, incidental, commercial or other damage, costs, fees, expenses or costs (“Damages”) caused
by Product and/or the Active Ingredient and/or the Auxiliary Materials to NITEC or any third party except to the extent that such Damages arise from the negligence or wilful misconduct of JAGOTEC, its Affiliates or any of its or their respective
employees. 

  

	12.3	 JAGOTEC assumes no liability vis a vis third parties, including without limitation, product liability, with respect to any and all Product or Finished
Product marketed, distributed, sold or used, directly or indirectly, and the 

  

 19. 

	 	 
Active Ingredient and Auxiliary Materials contained in any such Product or Finished Product. NITEC shall indemnify JAGOTEC from and against any and all losses, liabilities, damages and expenses
(including reasonable attorney’s fees and reasonable costs) that JAGOTEC suffers as a result of any claim, demand, action or other proceeding by any third party arising from or relating to NITEC’s actions regarding the manufacturing,
marketing, distribution, safe or use of Product, the Active Ingredient and/or Auxiliary Materials and/or Finished Product, or resulting from any breach of any of NITEC’s obligations and/or responsibilities and/or representations and warranties
hereunder, except to the extent that any such losses, liabilities, damages and expenses arise from the gross negligence or wilful misconduct of JAGOTEC. 

 

	12.4	Each of NITEC and JAGOTEC shall maintain, during the term of this Agreement and for a period of not less than five (5) years after its termination for what so ever
reason, liability insurance, including in the case of NITEC, product liability insurance, with respect to and covering their respective obligations contained in this Section 12, in such amount as is customary for companies undertaking similar
activities as the respective Party with products similar to Product. 

  

	13.	Confidentiality 

  

	13.1	Each Party has disclosed to the other party prior to the Effective Date, and will during the term of this Agreement continue to disclose, proprietary, confidential and
non-public information, including without limitation the Manufacturing Process, price calculations and other business and trade secrets (hereinafter, all collectively referred to as “Confidential Information”). 

 

	13.2	Each Party as recipient (the “Receiving Party”) of Confidential Information of the other Party (the “Disclosing Party”) hereby undertakes to
maintain in confidence all Confidential Information of the Disclosing Party and shall not use, disclose or grant or permit the use of any of the Confidential Information of the Disclosing Party except on a need-to-know basis to its directors,
officers, employees, agents, consultants, clinical investigators or other permitted contractors, to the extent such disclosure is reasonably necessary in connection with the activities of the Receiving Party as expressly authorized by this
Agreement. To the extent that disclosure is authorized by this Agreement, prior to disclosure, the Receiving Party shall obtain agreement in writing of any such person to hold in confidence and not make use of the Confidential Information of the
Disclosing Party for any purpose other than authorized by this Agreement. Each Receiving Party shall notify the Disclosing Party promptly upon the discovery of the unauthorized use or disclosure of any such Confidential Information of the Disclosing
Party. 

  

	13.3	 The obligations of confidentiality and non-use contained in Section 13.2 above shall not apply to the extent that (a) a Receiving Party
(i) is required to 

  

 20. 

	 	 
disclose the Confidential Information by law, regulation or order of a governmental agency or a court of competent jurisdiction, or (ii) is required to disclose Confidential Information of
the Disclosing Party to any Regulatory Authority for purposes of obtaining or maintaining registration for Product and/or Finished Product, provided that the Receiving Party shall request confidential treatment thereof (where available), or
(b) the Receiving Party can demonstrate by written or other tangible evidence that (i) the disclosed information of the Disclosing Party was public knowledge at the time of such disclosure to it, or thereafter became public knowledge,
other than as a result of actions of the Receiving Party, its directors, officers and employees in violation hereof; or (ii) the disclosed information was rightfully known by the Receiving Party (as shown by its written records) prior to the
date of disclosure to it by the Disclosing Party; or (iii) the disclosed information was developed or acquired by the Receiving Party independently of any knowledge or use of the Confidential Information of the Disclosing Party (as shown by its
written records); or (iv) the Confidential Information was previously legally provided to the Receiving Party by a third party without any obligations of confidentiality to the Disclosing Party. 

 

	13.4	The confidentiality obligations under this Section 13 shall be effective during the term of this Agreement and for a period of ten (10) years after the
termination hereof for any reason. Each Disclosing Party shall be entitled to injunctive remedies and relief against the Receiving Party and any third parties for any breach or threatened breach of the confidentiality obligations under this
Section 13 with respect to any of the Confidential Information of the Disclosing Party. 

  

	14.	Exclusivity 

 During the
term of this Agreement, JAGOTEC undertakes (a) not to engage in any production of Product for or on behalf of any third party and (b) to supply to NITEC all of NITEC requirements for the Product subject to the terms hereof. NITEC agrees to
order all its requirements for the Product from JAGOTEC (save as is otherwise provided herein). 
  

	15.	Miscellaneous Provisions 

  

	15.1	 Entire Agreement: The terms, covenants, conditions and provisions contained in this Agreement, including the Annexes referred to herein which
are agreed to form an integral part hereof, constitute the total and complete agreement of the Parties regarding the subject matter hereof and supersede all prior understandings and agreements hereto made, and there are no other representations,
understandings or agreements relating to the subject matter hereof. The provisions of this Agreement may not be waived, altered, amended 

 

 21. 

 
or repealed in whole or in part except by the written consent of both of the Parties to this Agreement. 
  

	15.2	Assignment: Save as set out below, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or
transferred by either Party without the prior written consent of the other Party. Either Party may assign in full all its rights and obligations hereunder to an Affiliate of that party (and only for so long as the assignee remains an Affiliate) and
if the assigning party remains fully liable to the other party for the full and timely performance of this Agreement by the party receiving assignment and any of such parties direct or indirect successors in interest. 

Any permitted assignee shall assume all obligations of its assignor under this Agreement or under the respective rights or obligations
actually assigned. 
  

	15.3	Notices: Any consent, notice or report required or permitted to be given or made under this Agreement by one Party to the other shall be in English and in
writing, delivered personally or by international courier service or by facsimile (promptly confirmed by personal delivery or international courier service) addressed to the other Party at its address indicated below, or to such other address as
shall have been notified in writing to the sending Party by the receiving Party from time to time, and shall take effect upon receipt by the addressee. 

  

			
	If to NITEC:	  	NITEC PHARMA AG
		  	Kägenstrasse 9
		  	CH 4153 Reinach
		  	Switzerland
		  	attn.: Jochen Mattis
		  	Tel: ++ 41 61 715.20.40
		  	Fax: ++ 41 61 715.20.49
		  	Email: jochen.mattis@nitecpharma.com
		
	If to JAGOTEC:	  	JAGOTEC AG
		  	Eptingerstrasse 51
		  	CH-4132 Muttenz,
		  	Switzerland
		  	attn.: Francesco Patalano
		  	Fax No: ++41 61 467 55 74
		
	With copy to:	  	SkyePharma Plc
		  	105 Piccadilly
		  	London W1J 7NJ
		  	Great Britain
		  	attn.: Group Counsel
		  	Fax No: ++44 20 7491 3338

  

	15.4	 Independent Contractors: It is expressly agreed that the Parties shall be independent contractors and that the relationship between the Parties
shall not 

  

 22. 

	 	 
constitute a partnership, joint venture or agency. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other Party, without the prior written consent of the other Party to do so. 

  

	15.5	NITEC warranty: NITEC warrants that it owns one hundred percent of the shares of Nitec Pharma GmbH. 

 

	15.6	Severability: Each Party hereby acknowledges that it does not intend to violate any public policy, statutory or common laws, rules, regulations, treaty or
decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid, the Parties hereto shall substitute, by mutual consent, valid
provisions for such invalid provisions which valid provisions in their economic effect are sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid
provisions. 

  

	15.7	Force Majeure: Neither Party hereto shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for
failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party including but not limited to fire, floods, embargoes, war,
acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labour disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or the other Party hereto.

  

	15.8	Headings: The titles and headings used in this Agreement are intended for convenience only and shall not in any way affect the meaning or construction of any
provision of this Agreement. 

  

	15.9	Waiver: The waiver by either Party hereto of any right hereunder or the failure to perform or of a breach by the other Party shall not be deemed a waiver of any
other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 

  

	16.	Dispute Resolution and Jurisdiction 

  

	16.1	In the event of any dispute arising between the Parties concerning this Agreement, the Parties agree that in the first place they shall meet for good faith discussions
in an attempt to negotiate an amicable solution. 

  

	16.2	 For any dispute arising between the Parties out of or in connection with this Agreement, or the interpretation, breach or enforcement thereof, which
cannot be amicably resolved pursuant to Section 16.1 above within two (2) months as from the first appearance of such dispute, the Parties agree and irrevocably 

 

 23. 

	 	 
submit to arbitration under the Rules of Arbitration of the International Chamber of Commerce (the “Rules”) by three (3) arbitrators appointed in accordance with the Rules. The
seat of arbitration shall be Basel, Switzerland, and any such arbitration shall be conducted in the English language. Any judgment upon the award rendered by the arbitrators shall be final and binding upon the parties and may be entered in any court
having jurisdiction thereof. 

  

	16.3	Notwithstanding anything contained in this Section 16, either Party may seek preliminary or injunctive measures or relief in any competent court having
jurisdiction. 

  

	17.	Applicable Law 

 The
Parties hereto agree that this Agreement shall be construed under and be governed by the laws of Switzerland, without reference to the principles of conflict of laws thereof, and shall not be governed by the United Nations Convention on Contracts
for the International Sale of Goods (the Vienna Convention of April 11, 1980). 
 IN WITNESS WHEREOF, the Parties have executed this
Agreement effective as of the Effective Date. 
  

									
	 For and on behalf of

JAGOTEC AG
	 		 		 	
			
	 /s/ Francesco PATALANO
	 		 	 [Illegible Signature]

	by:	 	Francesco PATALANO	 		 	by:	 	
	its:	 	Director ,3 Aug 07	 		 	its:	 	Director 3 Aug 07
				
	 For and on behalf of

NITEC PHARMA AG
	 		 		 	
			
	 /s/ Jochen Mattis 3.8.07
	 		 	 3 Aug 2007 /s/ Dr. Achim Schäffler

	by:	 	Jochen Mattis	 		 	by:	 	Dr. Achim Schäffler
	its:	 	Managing Director	 		 	its:	 	EVP RD and Manufacturing

  

 24. 

 List of Annexes: 

 

			
	Annex 1:	 	Presentations
		
	Annex 2:	 	Specifications
		
	Annex 2a:	 	Shelf Life Period
		
	Annex 3:	 	Minimum Orders
		
	Annex 4:	 	Prices
		
	Annex 5:	 	Quality Agreement
		
	Annex 6:	 	Commercial Yield
		
	Annex 7:	 	Logistics
		
	Annex 8:	 	Hygiene, Safety and Working conditions and Protection of the environment
		
	Annex 9:	 	Initial Members of the Committee
		
	Annex 10:	 	Statement of Storage Conditions

  

 25. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 1 
  

											
	PRESENTATION 	 		 		 		 		 	

  

	–	Lodotra 

  

	–	DOSAGE : 1,2,5 mg 

  

	–	Bulk tablets stored 30 L plastic drum 

  

 26. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 2a 
  

	
	Shelf Life Period

[...***...] 
  

 ***Confidential Treatment Requested 

27. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 2 
  

	
	Specifications

 

	–	[...***...] 

	–	[...***...] 

  

			
	 [...***...] 
	 	 [...***...] 

	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]
	[...***...]	 	[...***...]

  

 ***Confidential Treatment Requested 

28. 

 [...***...] 
  

							
	 [...***...] 
	  	 [...***...]
	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	[...***...]	  	[...***...]	  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  		  	

  

 ***Confidential Treatment Requested 

29. 

			
	[...**...]	 	[...***...]

  

 ***Confidential Treatment Requested 

30. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 3 
  

	
	MINIMUM ORDERS- for the
1st calendar year after Product approval and launch in the first
Major Country

 [...***...] 

 

	
	MINIMUM ORDERS- starting from the second calendar year after Product approval and launch in 3 out of 5 Major
Countries

 [...***...] 
  

 ***Confidential Treatment Requested 

31. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 4 
  

	
	 PRICES

  

	1.	The following prices relate to the packaged Product delivered Ex Works by JAGOTEC 

                [...***...] 

 
  

	2.	Payment shall be made in Euros by bank transfer within [...***...] of the invoice date, unless otherwise agreed between the parties. Bank transfer shall be made
to such account as Jagotec shall notify to Nitec. 

  

 ***Confidential Treatment Requested 

32. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 5 
  

	
	 QUALITY
AGREEMENT

 A Quality Agreement will be signed at the latest after manufacturing of the first campaign of the Product.

  

 33. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 6 
  

	
	MINIMUM COMMERCIAL YIELD

For active ingredient ordered by JAGOTEC on behalf of NITEC, the minimum commercial yield is as follows: 

 

	
	[...***...]            

composed of yield [...***...] 
  

 ***Confidential Treatment Requested 

34. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 7 

Distribution Specifications 
  

	
	LOGISTICS

Introduction: 
 In order to facilitate
transfer, storage, distribution and shipment of products which are the subject of the present contract, the following recommendations must be applied as from delivery of the first batch, failing this, JAGOTEC undertakes to apply these
recommendations within a period agreed with NITEC. 
 1 - Packaging: 

[...***...] 
 2 - Grouping
cartons: 
 The quantity shall be defined in the Quality Agreement (see annex 5). 

This quantity will be defined by NITEC in agreement with JAGOTEC. 

Identification of each drum will be carried out according to the provisions in the Quality Agreement (see annex 5). 

3 - Pallets: 
 [...***...]

 Any variation from this norm must be agreed in writing by NITEC. 

Consigned pallets are not accepted. NITEC can supply pallets to JAGOTEC if necessary. 

It is recommended to identify each pallet with similar label to those stuck on the drums. 

[...***...] 
  

 ***Confidential Treatment Requested 

35. 

 4 - Transport: 

If product delivery to NITEC is paid by JAGOTEC, it must use a carrier agreed by itself and only use sheet metal trailers. The carrier must be designed
for transporting medicines. 
 Documents necessary for a good reception must be joined: delivery notes, analysis certificates... 

JAGOTEC shall inform NITEC and NITEC’s partner for packaging by fax of all details concerning the load as soon as possible before the truck
departure. 
 5 - Modifications: 

Any modifications of points one to four above must be agreed by NITEC Distribution. At the very least the NITEC Distribution must be informed at the time
of the start up of the first Batch concerned, if it relates to a modification of regulations. 
 Each pallet of the modified first Batch must
undergo a supplementary special identification mentioning the type of modification. 
 6 - Detailed log book: 

NITEC can provide by simple request JAGOTEC a detailed log book. 
  

 36. 

 MANUFACTURING & SUPPLY AGREEMENT 

BETWEEN NITEC and JAGOTEC 

Annex 8 

Hygiene, Safety and Working conditions and Protection of the environment 

 

	1.	Hygiene, Safety and Working conditions: 

  

	1.1	JAGOTEC is held to know all the relevant legislative, regulatory or conventional requirements relating to hygiene, safety and working conditions, which it is required
to satisfy by reason of its activities hereunder. It undertakes to comply strictly with these at all times with regard to the provisions foreseen in the present contract. 

To this effect, JAGOTEC declares that it has received from NITEC the information which the latter has available concerning: 

 

	 	–	The particular hazards of the Active Ingredient or preparations thereof which are the subject of the present contract, as well as the procedures necessary for their use
or their manufacture 

  

	 	–	The provisions to take to provide against these hazards, notably the particular precautions necessary to take with regard to handling, use and, should the case arise,
storage 

  

	 	–	The rules for packaging and labelling which are applicable to them 

  

	 	–	The action to take in case of an accident 

This information is founded on existing scientific and technical knowledge, to which NITEC may have had reasonable access. 

 

	1.2	JAGOTEC must, with the least delay and by all means at its disposal, keep NITEC informed of: 

 

	 	–	All incidents or accidents occurring on the occasion of carrying out the provisions foreseen in the present contract, which causes harm to, or may cause harm to the
health and safety of workers 

  

	 	–	The emergency measures which, should the case arise, have been taken by itself or by the competent administrative authority 

According to the same terms JAGOTEC will bring to the knowledge of NITEC: 

All new facts in its actual knowledge concerning: 
  

 37. 

	 	–	the hazardous properties of substances or dangerous preparations which are the subject of the present contract, which result from the improvement of scientific or
technical understanding, or result from the observation of the effects of these products on the health of workers or the environment; 

  

	 	–	The possible modification of physicochemical or toxicological properties of these same substances or preparations, by reason notably of a change in the nature or
concentration of the impurities which they contain; 

 in each case having applied reasonable care to become aware
of developments and changes to the same. 
 In a reciprocal fashion NITEC will, with the least delay and by all means at its
disposal bring to the knowledge of JAGOTEC all information of the same type of which comes to be in possession 
  

	1.3	The parties will meet as often as necessary to examine together the conditions, and possibly the difficulties in the application of: 

 

	 	–	The legislative, regulatory or conventional dispositions relating to hygiene, safety and working conditions to which the provisions of the present contract are
subjected 

  

	 	–	The procedure for reciprocal exchange of information instituted in section 1.2 above 

Furthermore, each party will have the right to request of the other the holding of an ad hoc technical meeting in order to resolve all
questions that particularly relate to hygiene or to industrial safety, or to deal with an emergency situation, whatever the cause. The date and duration of this ad hoc technical meeting will be agreed jointly. 

 

	2.	Protection of the environment 

  

	2.1	JAGOTEC recognises expressly that, in order to have been duly authorised by the competent administrative authority or to have been so declared to it, all the
installations necessary for the execution of the provisions foreseen in the present contract comply with the legislative or regulatory dispositions to which they are subject with regard to the protection of the environment. 

In consequence, it undertakes to maintain this situation during the full duration of the contract and to be in a position to justify this
at any time to NITEC. 
  

	2.2	JAGOTEC will comply strictly, for all the provisions foreseen in the present contract, with all the legislative or regulatory dispositions relating to the disposal of
waste, the term “disposal” describing the operations of collection, transport, storage, sorting and treatment so as to avoid all harm to the environment, including in the long term. 

In particular JAGOTEC undertakes that it will ensure or get assurance that the waste which results from the provisions foreseen in the
present contract is treated only in installations duly authorised or accepted to this effect by the 
  

 38. 

 
competent administrative authority. It will be in a position to justify this at any time to NITEC. 
  

 39. 

 ANNEX 9 

INITIAL MEMBERS OF THE COMMITTEE 

NITEC 
 [...***...]

 JAGOTEC 
 [...***...]

  

 ***Confidential Treatment Requested 

40. 

 ANNEX 10 

Statement on the storage condition of Lodotra® tablets 

This statement clarifies the requirements of temperature-sensitive materials involved in the production of Lodotra bulk tablets (manufacturing site:
[...***...]), with regard to in-house storage and handling and shall prevail over any contrary provision in this Agreement 
 For
all batches of Product manufactured up to September 2007, the agreed storage conditions are and shall be at room temperature in accordance with USP. 

For all batches of Product manufactured after September 2007, the nominal storage condition of temperature-sensitive materials, i.e. 

– [...***...], 

including samples of these materials (e.g. batch release samples), shall be between [...***...] Compliance with this temperature range (subject to
the following) has to be ensured continuously throughout the presence of the above mentioned materials at the manufacturing site (Monitoring). Proof of this compliance has to be provided by SkyePharma (e.g. temperature curves). Deviations from the
nominal temperature range always require written documentation. 
 After September 2007 the nominal storage condition will not be exceeded by
more than [...***...] 
 The exceptions in the foregoing paragraph do not render temperature monitoring and documentation of deviations
from the nominal storage condition unnecessary. Correspondingly, Certificates of Compliance have to be supplemented by deviation reports and temperature monitoring data, if deviations occur. 

Nitec proposes the following measures to ensure and/or prove appropriate storage of the materials at the manufacturing site: 

 

	 	–	attachment of temperature loggers to the temperature-sensitive materials 

  

	 	–	use of mobile (validated) temperature container for storage 

  

 ***Confidential Treatment Requested 

41.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]